Simulations Plus (NASDAQ:SLP) Issues Earnings Results

Posted by on Jan 12th, 2021

Simulations Plus (NASDAQ:SLP) issued its earnings results on Sunday. The technology company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a net margin of 22.96% and a return on equity of 24.44%.

Shares of NASDAQ SLP opened at $79.33 on Tuesday. Simulations Plus has a 52 week low of $26.00 and a 52 week high of $83.78. The company has a market cap of $1.58 billion, a P/E ratio of 158.66, a P/E/G ratio of 7.63 and a beta of -0.17. The business has a 50-day simple moving average of $65.06 and a two-hundred day simple moving average of $65.43.

Several equities research analysts have recently weighed in on SLP shares. Taglich Brothers raised Simulations Plus from a “speculative buy” rating to a “buy” rating and set a $76.00 price target for the company in a research note on Wednesday, November 25th. Raymond James began coverage on Simulations Plus in a research report on Friday, October 16th. They set an “outperform” rating and a $95.00 target price on the stock. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a report on Thursday, November 19th. BidaskClub upgraded Simulations Plus from a “hold” rating to a “buy” rating in a report on Wednesday, December 23rd. Finally, Craig Hallum increased their price target on Simulations Plus from $75.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, November 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $80.40.

In other news, Director David L. Ralph sold 5,000 shares of the stock in a transaction dated Monday, November 30th. The shares were sold at an average price of $55.65, for a total value of $278,250.00. Following the sale, the director now directly owns 16,581 shares of the company’s stock, valued at $922,732.65. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Walter S. Woltosz sold 24,000 shares of the stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $68.95, for a total transaction of $1,654,800.00. Following the completion of the sale, the director now directly owns 4,707,359 shares in the company, valued at $324,572,403.05. The disclosure for this sale can be found here. Over the last three months, insiders sold 64,881 shares of company stock worth $4,347,992. Insiders own 31.57% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.

Recommended Story: Which market index is the best?

Earnings History for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.